The benefit of a formulation of azelaic acid 15% and a complex of active ingredients for the treatment of papulopustular rosacea
Phase 3
Completed
- Conditions
- Papulopustular rosacea phenotypeSkin and Connective Tissue Diseases
- Registration Number
- ISRCTN10669312
- Lead Sponsor
- ISISPHARMA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 69
Inclusion Criteria
1. Male or female subjects aged 18 years and older
2. Clinical diagnosis of papulopustular rosacea (PPR) phenotype with at least 10 inflammatory lesions
Exclusion Criteria
1. Pregnant or nursing woman
2. Subjects with rosacea of predominant phenotypes different from the phenotype of papules and pustules
3. Subjects with concomitant dermatoses that might interfere with the evaluation of lesions
4. Concomitant use of oral antibiotics and/or oral isotretinoin
5. Contraindications for the use of azelaic acid or metronidazole
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method